10-K: Claritev Reports 3.7% Revenue Growth, Navigates High Debt

Claritev Corporation reported a 3.7% increase in total revenue for 2025, reaching $965.4 million, alongside a significant reduction in net loss to $284.3 million, while addressing substantial indebtedness and internal control weaknesses.

Summary

• Total revenue increased by 3.7% to $965.4 million for the year ended December 31, 2025, up from $930.6 million in 2024.
• The company reported a net loss of $284.3 million for 2025, a substantial improvement from a net loss of $1,645.8 million in 2024.
• Adjusted EBITDA grew to $602.6 million in 2025, compared to $576.7 million in 2024.
• A major debt refinancing transaction was completed on January 30, 2025, which restructured existing debt and incurred $8.0 million in transaction costs in 2025.
• A 1-for-40 reverse stock split was effected on September 20, 2024.
• Claritev acquired OPCG, LLC on November 10, 2025, for $4.8 million in cash, adding healthcare program management and consulting expertise.
• The company identified $25.0 billion in potential medical cost savings on $179.8 billion in claim charges in 2025 through its core solutions.
• Claritev initiated its first international market expansion into the Middle East and North Africa (MENA) region in 2025 through a strategic partnership.
• Management identified material weaknesses in internal control over financial reporting as of December 31, 2025, related to IT general controls, specifically program change management and user access.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral-to-slightly-positive report. While revenue growth and a reduced net loss are encouraging, significant debt, rising G&A expenses, and identified internal control weaknesses temper the optimism.

Positives

• Total revenue increased by 3.7% year-over-year in 2025 to $965.4 million, indicating business growth.
• Net loss significantly reduced from $1,645.8 million in 2024 to $284.3 million in 2025, demonstrating improved financial performance.
• Adjusted EBITDA grew to $602.6 million in 2025, up from $576.7 million in 2024, reflecting stronger operational profitability.
• Successful completion of a major debt refinancing transaction on January 30, 2025, which restructured existing debt obligations.
• Expansion into the Middle East and North Africa (MENA) region through a strategic partnership, opening new geographic markets.
• Acquisition of OPCG, LLC for $4.8 million, enhancing healthcare program management and consulting expertise.
• Identified $25.0 billion in potential medical cost savings on $179.8 billion in claim charges in 2025, showcasing value to clients.
• Maintains strong client relationships with high renewal rates; top ten clients have been with the company for an average of over 20 years.
• Introduction of a new five-year share repurchase program for up to $75.0 million, with a $20.0 million cap per calendar year, starting January 1, 2026.
• The One Big Beautiful Bill Act (OBBBA) favorably impacted deferred tax assets by approximately $80.5 million as of December 31, 2025.

Negatives

• Reported a net loss of $284.3 million for the year ended December 31, 2025, indicating continued unprofitability.
• General and administrative expenses increased significantly by 46.8% to $221.5 million in 2025, primarily due to $45.0 million in Vision 2030 transformation costs and $16.9 million in antitrust-related legal costs.
• Interest expense increased by 20.1% to $392.0 million in 2025, primarily due to increased average indebtedness.
• Identified material weaknesses in internal control over financial reporting as of December 31, 2025, specifically regarding IT general controls (program change management and user access).
• Client concentration risk is high, with two clients individually accounting for 29.2% and 10.4% of total revenues in 2025.
• The company does not anticipate paying cash dividends on its Class A common stock in the foreseeable future.
• The market price of Class A common stock has significantly declined, with a $100 investment on December 31, 2020, being worth $13.4 by December 31, 2025.
• The company has substantial indebtedness, totaling $4,612.4 million in principal balance as of December 31, 2025.

Risks

• Success is dependent on retaining key clients; loss or significant reduction in business from largest clients could adversely affect results.
• Client contracts generally permit termination with short notice and do not contain minimum utilization requirements.
• Inability to achieve expected benefits from strategic plans, including Vision 2030 transformation plan, due to higher implementation expenses, delays, or failure to realize estimated savings.
• Failure to successfully enter new lines of business, launch new products, or broaden solution scope, potentially leading to unrecouped expenditures or management distraction.
• Inability to sustain sufficient liquidity to support operations and fulfill obligations.
• Adverse impact from trends in the U.S. healthcare system, such as reduced healthcare utilization and increased patient financial responsibility.
• Inability to identify, complete, and successfully integrate acquisitions, limiting business growth.
• Failure to successfully complete divestitures could negatively affect operations.
• Fragmented and competitive market for products and solutions, potentially leading to inability to maintain competitive position.
• Increased competition or pricing pressures could lead to declining growth and profits.
• Changes in the healthcare industry, including laws, regulations, and market shifts (e.g., towards HMOs, single-payer systems), could adversely affect the business.
• Evolving industry standards and rapid technological changes, including the adoption and further development of artificial intelligence, could reduce demand for products.
• Operating in a litigious environment, including potential lawsuits from healthcare providers, clients, or governmental investigations, which could be costly and divert management attention.
• Security breaches, loss of data, cyber incidents, or disruptions could compromise sensitive information, harm reputation, and create liability.
• Dependence on uninterrupted computer access for clients and reliable operation of IT systems; prolonged delays or revocation of software licenses could adversely affect operations.
• Failure to adequately protect trade secrets, know-how, proprietary applications, and business processes.
• Reliance on third-party cloud service providers (Oracle, AWS, Azure, Salesforce, SAP); disruptions could materially affect business.
• Inability to maintain licenses for third-party and open-source software, or unfavorable terms of open-source licenses.
• Constraints on expanding network and technology infrastructure could lead to client loss.
• Challenges with properly managing the use of AI could result in reputational harm, competitive harm, and legal liability.
• Potential lawsuits from third parties for alleged infringement of their proprietary rights.
• Failure to maintain an effective system of disclosure controls and internal control over financial reporting.
• Recent implementation of a new ERP system (SAP) may adversely affect business, results, or internal control effectiveness.
• Changes in accounting principles may negatively affect results of operations.
• Need to recognize impairment charges related to goodwill, identified intangible assets, and fixed assets.
• Changes in laws, regulations or rules, or a failure to comply with any laws, regulations or rules, may adversely affect business, investments and results of operations.
• Changes in tax laws or exposure to additional income tax liabilities.
• Inflation could adversely affect financial results, particularly wage-related pressures.
• Evolving awareness and focus on ESG practices, including anti-ESG sentiment, could affect business and reputation.
• Increased focus on sustainability issues, including climate change, may adversely affect business.
• Heightened enforcement activity by federal and state agencies may increase exposure to lawsuits and investigations.
• Risk that state authorities may find contractual relationships with physicians violate laws prohibiting corporate practice of medicine and fee-splitting.
• Federal and state regulators may investigate payment of out-of-network claims or NSA compliance.
• Substantial level of indebtedness and current leverage may limit ability to raise additional capital or react to economic changes.
• Inability to generate sufficient cash to service all indebtedness, potentially forcing asset sales or refinancing.
• Debt agreements contain restrictions limiting flexibility in operating the business.
• Lowering or withdrawal of credit ratings may increase borrowing costs and reduce access to capital.
• Ability to incur substantially more indebtedness despite current leverage.
• Variable rate indebtedness subjects the company to interest rate risk, despite swaps.
• H&F and the Sponsor beneficially own a significant equity interest (24.8% voting equity) and their interests may conflict with other shareholders.
• Limited ability to issue equity awards to employees due to insufficient shares in the 2020 Omnibus Incentive Plan.
• Subject to securities or other stockholder litigation, which is expensive and diverts management attention.
• Charter designates Delaware state court as exclusive forum for certain actions, potentially limiting stockholders' ability to obtain a favorable judicial forum.
• Provisions in organizational documents, debt agreements, and Investor Rights Agreement could delay or prevent a change of control.
• Board authorized to issue preferred stock without stockholder approval, potentially impeding acquisitions.
• No anticipated cash dividends on Class A common stock in the foreseeable future.
• Market price for Class A common stock may be volatile and decline.
• Any sale of Class A common stock by a significant stockholder could cause the market price to drop.
• Risks associated with international expansion, including managing foreign operations, compliance with laws (e.g., FCPA), and political/economic instability.
• Financial results negatively impacted by global events beyond control (e.g., trade relationships, military conflict, public health crises).

Future Outlook

Claritev's Vision 2030 strategic plan aims to transform the company into a technology and data insights leader, focusing on increasing transparency, affordability, and quality across the healthcare ecosystem. The company plans to drive value in core offerings, accelerate new product development leveraging existing data and distribution, expand into new geographic markets like MENA, achieve financial and operational excellence, attract high-quality talent, and promote innovation using advanced technologies. The year 2026 is branded 'THE WAY UP,' with a focus on maintaining company momentum across all aspects of Vision 2030.

Management Comments

• "We branded 2025 as THE TURN and the year represented a return to year-over-year revenue growth, with an expanded and more experienced management team and a company-wide commitment to operating a Market-Informed, Product-Led, Partner-Enabled and Technology-Driven business to bring Vision 2030 to life and unlock the growth potential of our unique data assets and capabilities."
• "We have branded 2026 as THE WAY UP and will be focused on maintaining our Company momentum across all aspects of Vision 2030 throughout the year."
• "Senior management of Claritev believes it has established a culture where cybersecurity risk management is prioritized, the establishment and enforcement of information security strategies, policies, standards, and procedures is supported, and the individuals with responsibility for the same are empowered."

Industry Context

StockSavvy.ai notes that Claritev operates within a U.S. healthcare market projected to grow significantly, reaching over $8.6 trillion by 2033, driven by an aging population, increased insured population, new treatments, and medical inflation. The company's focus on transparency, affordability, and payment accuracy directly addresses the estimated 25% waste in U.S. healthcare spending. Its expansion into AI-driven solutions and international markets aligns with broader industry trends towards technological innovation and global reach in healthcare services, positioning it against competitors like Optum, Conduent, Cotiviti, and various regional PPO networks.

Comparison to Industry Standards

• Claritev's PHCS Network has been continuously accredited for credentialing by the National Committee for Quality Assurance (NCQA) since 2001, indicating a high standard for provider quality.
• The company processes approximately 30 million claims monthly, with 99% of proprietary network repriced claims and 97% of reference-based pricing solutions returned within one day, demonstrating high operational efficiency compared to industry benchmarks.
• Claritev's platform integrates deeply with client technology environments, occupying a unique pre-payment position in the workflow, which is a competitive differentiator against many payment integrity competitors who originated as post-payment specialists.
• The company believes no single competitor currently offers the same breadth of out-of-network cost management services it provides, suggesting a broad solution portfolio compared to specialized competitors like 6Degrees, Advanced Medical Pricing Solutions, ELAP Services, Payer Compass, Zelis, ClearHealth Strategies, and Naviguard.
• In data and analytics, PlanOptix competes with a strategic alliance between Turquoise Health and Milliman, while BenInsights data warehouse and analytics solutions compete with Cotiviti, HDMS, Artemis, and Merative. Risk modeling and digital underwriting solutions compete with Milliman, Gradient AI, 3M, and John Hopkins ACG.

Management Changes

Corporate Governance

Legal Proceedings

• Claritev is a defendant in various lawsuits and other pending and threatened litigation, including putative class action lawsuits alleging antitrust violations.
• These antitrust lawsuits claim the company is conspiring with commercial health insurance payers to suppress out-of-network reimbursements.
• The antitrust lawsuits have been centralized in the Northern District of Illinois.
• Motions to dismiss the consolidated antitrust complaints were granted in part and denied in part on June 3, 2025.
• Discovery in the antitrust case is ongoing, and management believes these lawsuits are without merit and is vigorously defending the company.

Related Party Transactions

• Hellman & Friedman Capital Partners VIII, L.P. (H&F) and Churchill Sponsor III, LLC (Sponsor) collectively control approximately 24.8% of Claritev's voting equity, giving them significant influence over corporate decisions.
• The company's second amended and restated certificate of incorporation allows H&F and the Sponsor, and their affiliates, to engage in competitive businesses and renounces any entitlement to corporate opportunities not expressly offered to them in their capacities as directors or officers.
• The Investor Rights Agreement grants H&F and Sponsor certain registration rights, including demand, piggy-back, and shelf registration rights, which may facilitate the sale of a significant portion of Class A common stock by these holders.

Stakeholder Impact

• Shareholders: Potential for stock price volatility due to market factors, significant stockholder sales, and ongoing litigation. No anticipated dividends. Impacted by reverse stock split.
• Employees: Impacted by Vision 2030 transformation plan, which includes internal personnel costs and potential organizational changes. Stock-based compensation is a key incentive, but limited available shares for future grants could affect motivation.
• Clients (Payers, Employers/Plan Sponsors): Benefit from Claritev's solutions in reducing medical costs and improving billing accuracy. Subject to regulatory changes (e.g., NSA, MHPAEA) which Claritev helps them comply with. Risk of client attrition or reduced utilization impacting Claritev's revenue.
• Providers: Affected by Claritev's cost management techniques and negotiation services. May experience reduced discounts or increased resistance to cost management.
• Creditors: Impacted by the company's substantial indebtedness and debt covenants. Refinancing transaction altered debt structure.
• Regulatory Authorities: Company is subject to extensive federal and state healthcare regulations, privacy laws (HIPAA, HITECH, CCPA, CPRA), and antitrust laws. Compliance failures could lead to significant liability.

Next Steps

• Maintain company momentum across all aspects of Vision 2030 throughout 2026 ('THE WAY UP').
• Propose an increase in shares available for grants under the 2020 Omnibus Incentive Plan at the 2026 Annual Meeting of Stockholders.
• Actively develop and implement a remediation plan to strengthen IT general control processes and controls during fiscal year 2026.
• Continue to monitor the impact of the OBBBA and anticipated future guidance from the U.S. Department of the Treasury.
• Continue to adapt to evolving NSA regulations and support clients with compliance documentation for MHPAEA.
• The substantial IDR operations proposed rule addressing aspects of the IDR process is likely to be finalized in 2026, which will require updates to processes and impose additional compliance obligations for payer clients.

Key Dates

Recommendation

Claritev's 2025 results show a positive trend with revenue growth and a significantly reduced net loss, indicating progress on its Vision 2030 strategy. The debt refinancing provides some stability. However, the company still operates at a net loss, faces substantial debt, and has identified material weaknesses in internal controls. The ongoing antitrust litigation and client concentration also present notable risks. While strategic initiatives like international expansion and AI integration offer long-term potential, the current financial position and operational challenges warrant a 'hold' recommendation. Investors should monitor the successful remediation of internal control weaknesses, progress on Vision 2030, and the outcome of legal proceedings before considering further investment.

Keywords

Healthcare Technology, Data Analytics, Cost Management, SEC Filing, 10-K, Claritev Corporation, Financial Performance, Debt Refinancing, Reverse Stock Split, Cybersecurity, Risk Management, Corporate Governance, AI in Healthcare, PPO Networks, Claims Intelligence, Payment Integrity, Revenue Integrity, Strategic Plan, Vision 2030, Share Repurchase, Delaware Law, NYSE